Literature DB >> 14677049

Combined effects of PPARgamma2 P12A and PPARalpha L162V polymorphisms on glucose and insulin homeostasis: the Québec Family Study.

Yohan Bossé1,2, S John Weisnagel3,4, Claude Bouchard5, Jean-Pierre Després1,2,6, Louis Pérusse3, Marie-Claude Vohl7,8.   

Abstract

Peroxisome proliferator-activated receptors gamma2 and alpha are nuclear factors known to be important regulators of lipid and glucose metabolism. Two polymorphisms, namely PPARgamma2 P12A and PPARalpha L162V, were investigated for their individual and interaction effects on glucose and insulin homeostasis. Genotypes were determined in 663 nondiabetic adults participating in the Québec Family Study and who underwent an oral glucose tolerance test (OGTT). The insulin and C-peptide areas under the curve (AUC) following the OGTT were higher in subjects carrying the PPARalpha V162 allele compared to homozygous for the L162 allele. When subjects were grouped according to both polymorphisms, higher levels of insulin and C-peptide during the OGTT were observed for those carrying the PPARalpha V162 allele except when they carry at the same time the PPARgamma2 A12 allele. Thus, the PPARgamma2 A12 allele seems protective against the deleterious effect of the PPARalpha V162 allele. Furthermore, a significant gene-gene interaction was observed for the acute (0-30 min) (p<0.001) and the total (p=0.05) C-peptide AUC following the OGTT. These results provide evidence of a gene-gene interaction in the regulation of plasma glucose-insulin homeostasis, and emphasize that these interactions need to be taken into account when dissecting the genetic etiology of complex disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14677049     DOI: 10.1007/s10038-003-0087-2

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  38 in total

1.  Interactions between variants in the beta3-adrenergic receptor and peroxisome proliferator-activated receptor-gamma2 genes and obesity.

Authors:  W C Hsueh; S A Cole; A R Shuldiner; B A Beamer; J Blangero; J E Hixson; J W MacCluer; B D Mitchell
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

2.  Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity.

Authors:  M Guerre-Millo; P Gervois; E Raspé; L Madsen; P Poulain; B Derudas; J M Herbert; D A Winegar; T M Willson; J C Fruchart; R K Berge; B Staels
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

3.  Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects.

Authors:  D M Flavell; I Pineda Torra; Y Jamshidi; D Evans; J R Diamond; R S Elkeles; S R Bujac; G Miller; P J Talmud; B Staels; S E Humphries
Journal:  Diabetologia       Date:  2000-05       Impact factor: 10.122

Review 4.  Peroxisome proliferator-activated receptors, orphans with ligands and functions.

Authors:  K Schoonjans; G Martin; B Staels; J Auwerx
Journal:  Curr Opin Lipidol       Date:  1997-06       Impact factor: 4.776

5.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

6.  Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes.

Authors:  F P Mancini; O Vaccaro; L Sabatino; A Tufano; A A Rivellese; G Riccardi; V Colantuoni
Journal:  Diabetes       Date:  1999-07       Impact factor: 9.461

7.  The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects.

Authors:  M Koch; K Rett; E Maerker; A Volk; K Haist; M Deninger; W Renn; H U Häring
Journal:  Diabetologia       Date:  1999-06       Impact factor: 10.122

Review 8.  The mechanisms of action of PPARs.

Authors:  Joel Berger; David E Moller
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

9.  The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.

Authors:  H Mori; H Ikegami; Y Kawaguchi; S Seino; N Yokoi; J Takeda; I Inoue; Y Seino; K Yasuda; T Hanafusa; K Yamagata; T Awata; T Kadowaki; K Hara; N Yamada; T Gotoda; N Iwasaki; Y Iwamoto; T Sanke; K Nanjo; Y Oka; A Matsutani; E Maeda; M Kasuga
Journal:  Diabetes       Date:  2001-04       Impact factor: 9.461

Review 10.  The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism.

Authors:  Michael Stumvoll; Hans Häring
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

View more
  4 in total

1.  Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study.

Authors:  Amanda K Golembesky; Marilie D Gammon; Kari E North; Jeannette T Bensen; Jane C Schroeder; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  Carcinogenesis       Date:  2008-06-26       Impact factor: 4.944

Review 2.  Monogenic Diabetes: What It Teaches Us on the Common Forms of Type 1 and Type 2 Diabetes.

Authors:  Yisheng Yang; Lawrence Chan
Journal:  Endocr Rev       Date:  2016-04-01       Impact factor: 19.871

3.  Interaction Effects of the Leu162Val PPAR α and Pro12Ala PPAR γ 2 Gene Variants with Renal Function in Metabolic Syndrome Population.

Authors:  Sarraj Mohamed Youssef; Najah Mohamed; Slimani Afef; Ben Hamda Khaldoun; Neffati Fadoua; Najjar Mohamed Fadhel; Slimane Mohamed Naceur
Journal:  PPAR Res       Date:  2013-04-04       Impact factor: 4.964

4.  PPARγ2 polymorphism and human health.

Authors:  Weimin He
Journal:  PPAR Res       Date:  2009-04-16       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.